D.E. Shaw & Co
SAGE

D.E. Shaw & Co’s Sage Therapeutics SAGE Stock Holding History

D.E. Shaw & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,917,284
Closed -$17.5M – 4874
2025
Q2 		$17.5M Sell
1,917,284
-170,159
-8% -$1.25M 0.01% 1121
2025
Q1 		$16.6M Buy
2,087,443
+1,367,338
+190% +$10M 0.01% 1053
2024
Q4 		$3.91M Buy
720,105
+73,073
+11% +$447K ﹤0.01% 2182
2024
Q3 		$4.67M Buy
647,032
+322,761
+100% +$2.95M ﹤0.01% 1997
2024
Q2 		$3.52M Buy
324,271
+164,933
+104% +$2.11M ﹤0.01% 2130
2024
Q1 		$2.99M Sell
159,338
-95,329
-37% -$2.2M ﹤0.01% 2301
2023
Q4 		$5.52M Buy
254,667
+52,465
+26% +$1.04M ﹤0.01% 1828
2023
Q3 		$4.16M Sell
202,202
-249,070
-55% -$7.19M ﹤0.01% 1964
2023
Q2 		$21.2M Buy
451,272
+3,037
+0.7% +$151K 0.02% 832
2023
Q1 		$18.8M Sell
448,235
-141,214
-24% -$6.07M 0.02% 934
2022
Q4 		$22.5M Sell
589,449
-112,035
-16% -$4.28M 0.02% 850
2022
Q3 		$27.5M Sell
701,484
-59,201
-8% -$2.29M 0.03% 673
2022
Q2 		$24.6M Sell
760,685
-165,851
-18% -$5.56M 0.03% 737
2022
Q1 		$30.7M Sell
926,536
-67,733
-7% -$2.55M 0.03% 743
2021
Q4 		$42.3M Sell
994,269
-262,022
-21% -$11M 0.04% 635
2021
Q3 		$55.7M Sell
1,256,291
-60,852
-5% -$2.79M 0.05% 480
2021
Q2 		$74.8M Sell
1,317,143
-554,732
-30% -$39.2M 0.06% 370
2021
Q1 		$140M Sell
1,871,875
-323,012
-15% -$26.5M 0.14% 156
2020
Q4 		$190M Sell
2,194,887
-268,179
-11% -$19.8M 0.17% 110
2020
Q3 		$151M Buy
2,463,066
+340,910
+16% +$17.3M 0.15% 129
2020
Q2 		$88.2M Buy
2,122,156
+1,708,926
+414% +$62M 0.11% 208
2020
Q1 		$11.9M Buy
413,230
+336,537
+439% +$19.5M 0.02% 899
2019
Q4 		$5.54M Sell
76,693
-26,950
-26% -$3.32M 0.01% 1652
2019
Q3 		$14.5M Buy
+103,643
New +$17.3M 0.02% 942
2018
Q4 		– Sell
-1,546
Closed -$177K – 3958
2018
Q3 		$218K Sell
1,546
-97,363
-98% -$15M ﹤0.01% 3508
2018
Q2 		$15.5M Buy
98,909
+92,366
+1,412% +$14.5M 0.02% 858
2018
Q1 		$1.05M Sell
6,543
-31,500
-83% -$5.35M ﹤0.01% 2452
2017
Q4 		$6.27M Buy
+38,043
New +$3.69M 0.01% 1337
2017
Q3 		– Sell
-64,597
Closed -$5.07M – 3583
2017
Q2 		$5.14M Buy
64,597
+32,882
+104% +$2.38M 0.01% 1311
2017
Q1 		$2.25M Sell
31,715
-4,285
-12% -$251K ﹤0.01% 1767
2016
Q4 		$1.84M Buy
36,000
+25,975
+259% +$1.22M ﹤0.01% 2053
2016
Q3 		$462K Sell
10,025
-6,953
-41% -$283K ﹤0.01% 2844
2016
Q2 		$512K Buy
+16,978
New +$566K ﹤0.01% 2785
2016
Q1 		– Sell
-5,878
Closed -$343K – 3730
2015
Q4 		$343K Buy
+5,878
New +$291K ﹤0.01% 3304

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's SAGE Position: Q3 2025 in Review

D.E. Shaw & Co sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,917,284 shares — an estimated $17.5M sold.

D.E. Shaw & Co first reported a position in SAGE in Q4 2015 and held it in 34 quarters. The position peaked at $190M in Q4 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • D.E. Shaw & Co reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,917,284 Sage Therapeutics shares in Q3 2025, an estimated $17.5M.
  • D.E. Shaw & Co first reported a position in Sage Therapeutics in Q4 2015 and held it in 34 quarters.
  • D.E. Shaw & Co's Sage Therapeutics position peaked at $190M in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.